Trials / Completed
CompletedNCT00385203
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
An Open-Label, Phase II Study to Evaluate the Biological Activity of Cediranib (AZD2171) as Measured by [F 18] Fluoro 2 Deoxy D Glucose - Positron Emission Tomography (FDG-PET) Response, in Patients With Metastatic Gastro-Intestinal Stromal Tumours (GIST) Resistant or Intolerant to Imatinib Mesylate
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the anti-tumour activity and biological effects of cediranib (AZD2171) at a dose of 45mg, primarily in Gastrointestinal Stromal Tumour (GIST) patients who are resistant to imatinib mesylate (current standard therapy) and also in patients with metastatic Soft Tissue Sarcoma (STS) resistant to standard therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD2171 | 45 mg oral tablet once daily dose |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2008-06-01
- Completion
- 2009-12-01
- First posted
- 2006-10-06
- Last updated
- 2012-07-16
- Results posted
- 2012-07-16
Locations
2 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00385203. Inclusion in this directory is not an endorsement.